Literature DB >> 14616835

Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid.

Y-C Chan1, Y-J Sun, P P-L Ng, S-H Tan.   

Abstract

This prospective study investigated patients with a clinical diagnosis of bullous pemphigoid (BP) who presented to a tertiary dermatology referral centre in Singapore. All patients had blood samples and skin biopsies taken for histology, immunofluorescence (IF) and immunoblot analysis prior to initiation of treatment. We analysed 23 new cases of BP during the 1-year study period. Seventeen of 22 biopsy specimens showed subepidermal blister formation, and 12 of the 17 (71%) had a predominance of eosinophils (>50%) in the blister cavity. The dermal inflammatory infiltrate of 22 biopsy specimens was predominantly lymphocytic in nine (41%) and eosinophilic in eight (36%). The histological picture was highly suggestive of BP in 15 of 22 patients (68%), suggestive in two (9%) and poorly suggestive in five (23%). Twenty-one of 23 (91%) patients had linear deposits of IgG and C3 along the dermo-epidermal junction. Serum indirect IF was positive in 22 of 23 (96%) patients, all showing antibody binding to the roof of the induced blister on salt-split skin. All of the 23 serum samples demonstrated positive immunoblot reactivity to BP180 and/or BP230 from epidermal extracts of normal human skin. Immunoblot reactivity with BP180 and BP230 was 78% (n=18) and 52% (n=12), respectively. The BP180 NC16A antibody could be detected in 22 of 23 (96%) sera using the enzyme-linked immunosorbent assay (ELISA) technique. The sensitivity of traditional diagnostic techniques, i.e. direct IF (91%) and indirect IF (96%), was comparable with that of the newer techniques, i.e. immunoblot analysis (100%) and ELISA (96%). ELISA in combination with routine indirect IF may be a useful diagnostic tool in patients with suspected BP who refuse a skin biopsy but consent to give a serum sample.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616835     DOI: 10.1046/j.1365-2230.2003.01419.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

1.  Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid: A pilot study.

Authors:  Alvise Sernicola; Irene Russo; Andrea Saponeri; Mauro Alaibac
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 2.  Serological Diagnosis of Autoimmune Bullous Skin Diseases.

Authors:  Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

3.  Bullous pemphigoid diagnosis: the role of routine formalin-fixed paraffin-embedded skin tissue immunochemistry.

Authors:  Harim Oh; Chul Hwan Kim; Yoo Jin Lee
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

Review 4.  The significance of preclinical anti-BP180 autoantibodies.

Authors:  Yosuke Mai; Kentaro Izumi; Shoko Mai; Hideyuki Ujiie
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.